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Background: The ABL kinase inhibitor imatinib is highly effective in treating most, but not all, patients with chronic
myeloid leukemia (CML). This is because residual CML cells are generally present in the bone marrow
microenvironment and are refractory to imatinib. Hematopoietic cytokine receptor signaling is mediated by Janus
kinases (JAKs) and their downstream transcription factor, signal transducer and activator of transcription (STAT).
TG101348 (SAR302503) is an oral inhibitor of JAK2.
Methods: We investigated the efficacy of imatinib and TG101348 using the break point cluster region-c-Abelson
(BCR-ABL)-positive cell line and primary CML samples wherein leukemia cells were protected by a feeder cell line (HS-5).
Results: Imatinib treatment resulted in partial inhibition of cell growth in HS-5-conditioned medium. Furthermore,
combined treatment with imatinib and TG101348 abrogated the protective effects of HS-5-conditioned medium on
K562 cells. Phosphorylation of Crk-L, a BCR-ABL substrate, decreased considerably, while apoptosis increased. In addition,
the combined treatment of CD34-positive primary samples resulted in considerably increased cytotoxicity, decreased
Crk-L phosphorylation, and increased apoptosis. We also investigated TG101348 activity against feeder cells and
observed that STAT5 phosphorylation, granulocyte macrophage colony-stimulating factor, and interleukin 6 levels
decreased, indicating reduced cytokine production in HS-5 cells treated with TG101348.
Conclusions: These results showed that JAK inhibitors may enhance the cytotoxic effect of imatinib against residual
CML cells and that a combined approach may be a powerful strategy against the stroma-associated drug resistance of
Philadelphia chromosome-positive cells.
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Chronic myeloid leukemia (CML) is a malignant myelo-
proliferative clonal disorder associated with the presence
of the Philadelphia chromosome (Ph) [1]. Ph results from
a translocation that yields the break point cluster region-
c-Abelson (BCR-ABL) fusion protein, which is a constitu-
tively active tyrosine kinase [2]. BCR-ABL activation is
responsible for modulating different signaling pathways,
and consequently, hematopoietic stem and progenitor cell
proliferation, as well as abnormal interactions with the
extracellular matrix and stroma [3]. The BCR-ABL fusion
protein activates several downstream signaling molecules,* Correspondence: okabe@tokyo-med.ac.jp
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unless otherwise stated.including those of the Ras/Raf/MAPK, PI3K/AKT/mTOR,
and JAK/STAT pathways [4-6].
Imatinib, a first generation ABL tyrosine kinase inhibitor
(ABL TKI), is a competitive inhibitor that binds to the
ATP-binding catalytic site of ABL and decreases kinase
domain activity by stabilizing the protein in an active con-
formation [7]. Imatinib is highly for treating patients in the
chronic phase of CML. As observed in the International
Randomized Study of Interferon and STI571 study, 87% of
patients treated with imatinib achieved a complete cyto-
genetic response, with many patients achieving major mo-
lecular responses [8]. However, discontinuing imatinib is
usually associated with disease relapse. In particular, the
French Stop Imatinib trial reported that approximately
60% of patients who had maintained a complete molecularLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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of treatment [9]. Thus, it is currently recommended that
patients with CML stop TKI therapy only in the context of
a clinical trial. The major cause of relapse in patients with
CML is considered to be the existence of leukemia stem
cells as imatinib is believed to be unable to kill quiescent
CML stem cells. It is possible that these quiescent
leukemia stem cells do not depend on BCR-ABL signaling
[10]. Therefore, new strategies are required to specifically
target CML stem cells and improve outcomes in patients
with CML.
Janus kinases (JAKs) are a family of intracellular, non-
receptor tyrosine kinases including four family mem-
bers such as JAK1, JAK2, JAK3, and Tyk2. JAK signaling
pathways are required for cytokine and growth factor
signaling [11]. The downstream molecules, which be-
long to the signal transducer and activator of transcrip-
tion (STAT) family, are activated by JAKs. The JAK/
STAT pathway is responsible for various functions.
JAK2 plays an important role in the signaling pathways
induced by hematopoietic growth factors such as granulo-
cyte macrophage colony-stimulating factor (GM-CSF) and
interleukin (IL)-3 [12,13]. Although JAK2 is phosphory-
lated in cytokine-independent BCR-ABL-positive CML
cells, aberrant JAK/STAT signaling has been implicated in
various tumors [14]. For example, a point mutation in
JAK2 that results in non-synonymous amino acid substitu-
tion, V617F, was discovered in hematological malignan-
cies. In fact, the V617F variant is common in patients with
myeloproliferative neoplasms (MPNs) such as polycythemia
vera, essential thrombocythemia, and primary myelofibro-
sis [15]. Several JAK2 inhibitors have been developed for
patients with MPNs. These inhibitors are currently in clin-
ical trials. One of the JAK2 inhibitors, TG101348 (also
known as SAR302503), is a small-molecule JAK2 antagon-
ist. TG101348 inhibits the growth of hematopoietic cells
derived from patients with MPNs who have the V617F
mutation [16].
JAK2 is part of the BCR-ABL signaling network path-
way and is activated in CML cells [17]. JAK2 including
the point mutation is also involved in CML maintenance
[18-20]. Thus, JAK2 inhibitors may become a thera-
peutic target for CML cells. Although several reports
have demonstrated that BCR-ABL/JAK2 inhibits CML
cells including ABL TKI-resistant cells [21,22], it is not
completely known whether JAK2 is involved in CML
stem cell survival mediated by cytokines in the presence
of ABL TKI.
Here, we investigated the effect of TG101348 on re-
sidual CML cells. We demonstrated that co-treatment
with imatinib and TG101348 increased the cytotoxic ef-
fect in CD34-positive CML samples. We also found that
cytokine production, which supported growth of CML
cells, was reduced by TG101348.Results
Effects of imatinib on BCR-ABL-expressing cells in the
presence of human stromal cells
We investigated the cell proliferation effects of imatinib
on K562 cells when cultured in the presence or absence
of HS-5 conditioned medium, which was collected and
pooled from a HS-5 stromal cell culture. We found that
K562 cell proliferation was inhibited by imatinib in a
dose-dependent manner when cultured in the absence of
HS-5 conditioned medium (Figure 1A). In contrast, we
observed that anti-leukemic activity of imatinib was par-
tially reduced in the presence of HS-5 conditioned
medium (Figure 1A). The HS-5 stromal cell line secretes
several cytokines [23]. As JAK2 is essential for signaling
of several of these cytokines, we used the JAK2 inhibitor
TG101348 to investigate the role of JAK2 in the ob-
served protection of K562 cells by HS-5 conditioned
medium. We found that co-treatment with imatinib and
TG101348 inhibited K562 cell proliferation in the pres-
ence of the HS-5 conditioned medium (Figure 1B). We
also found that another JAK inhibitor, AG490, also
inhibited K562 cell growth in the presence of HS-5 con-
ditioned medium (Figure 1B). We next investigated the
effect of TG101348 alone on K562 cells. We found that
high TG101348 concentration partially inhibited K562
cell proliferation in the absence of the HS-5 conditioned
medium (Figure 1C). The IC50 value for TG101348 was
up to 2 μM in BCR-ABL-positive cells. The concentra-
tion of TG101348 used in a clinical trial was >1 μM
[16]. It has been reported that a high TG101348 concen-
tration is associated with severe adverse events in pa-
tients with MF [16], thus, we investigated concentrations
below <1 μM in this study. Next, we investigated the effects
of this inhibitor on intracellular signaling. We observed a
decrease in BCR-ABL and STAT5 phosphorylation in the
presence of a high TG101348 concentration (Figure 1D).
Treatment of Ph-positive (Ph+) leukemia cells with
imatinib and TG101348
We next investigated whether imatinib and TG101348
could inhibit Ph + cell growth in the presence of HS-5
cells. K562 cells were exposed to imatinib alone or in
combination with TG101348 at different concentrations
in the presence or absence of HS-5 cells. Growth of
K562 cells treated with imatinib alone in the absence of
HS-5 was considerably inhibited in a dose-dependent
manner. However, when K562 cells were treated in the
presence of HS-5 cells, the effects of imatinib decreased
considerably (Figure 2A). Thus, HS-5 cells supported
K562 cell proliferation even in the presence of a high
imatinib concentration. Next, we investigated the effect
of TG101348 treatment. We observed that cell contact
between K652 and HS-5 cells was required for protec-
tion from imatinib. We also found that treatment with
Figure 1 Cytotoxic effects of imatinib in the presence of HS-5 conditioned medium. (A) K562 cells were cultured at a concentration of 8 ×
104/mL in the presence of varying concentrations of imatinib in the presence or absence of HS-5 conditioned medium for 72 h. Viable cell
numbers were calculated. Results are representative of three separate experiments. (B) K562 cells were treated with 2 μM imatinib alone or in
combination with either 1 μM TG101348 or 5 μM AG490 in the presence or absence of HS-5 conditioned medium for 72 h. Viable cell numbers
were calculated. Results are representative of three separate experiments. (C) K562 cells were cultured with the indicated concentrations of
TG101348 for 72 h. Viable cell numbers were calculated. Results are representative of three separate experiments. (D) K562 cells were treated with
TG101348 for 24 h, and total extracts were examined by immunoblotting using anti-phospho ABL, ABL, phospho-STAT5, STAT5, and β-actin Abs.
Blots were scanned and optical densities were determined using ImageJ software.
Okabe et al. Journal of Hematology & Oncology 2014, 7:37 Page 3 of 11
http://www.jhoonline.org/content/7/1/37TG101348 overcame the HS-5-mediated protection of
K562 cells (Figure 2A). Using immunoblotting, we deter-
mined that phosphorylation of Crk-L, a BCR-ABL sub-
strate, STAT5, and mitogen activated protein kinase
(MAPK) decreased following co-treatment with imatinib
and TG101348. In contrast, we observed that poly(ADP-
ribose) polymerase (PARP) activity increased during co-
treatment (Figure 2B). Next, we used the pan-caspase
inhibitor Z-VAD-fmk to inhibit caspase pathways. We
found that Z-VAD-fmk treatment inhibited imatinib- and
TG101348-induced apoptosis, suggesting that a caspase-
dependent mechanism is involved in TG101348- and
imatinib-mediated cell death in K562 cells (Figure 2C).Effects of TG101348 in combination with imatinib on
CD34-positive CML samples
To determine whether co-treatment with TG101348
and imatinib affects primary chronic phase CML cell
viability, we isolated untreated peripheral blood samples
from patients at the time of diagnosis or healthy donors
and cultured the cells in the presence of HS-5 cells for
72 h with either imatinib alone or in combination with
TG101348 at the indicated concentrations (Figure 3A).
Cell viability was assessed by trypan blue exclusion. Via-
bility of CD34-positive primary cells was not affected by
imatinib treatment alone or in the presence of HS-5
stromal cells (Figure 3A). In contrast, viability of the
Figure 2 (See legend on next page.)
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Figure 2 Co-treatment with imatinib and TG101348 increased inhibition of cell growth and induced apoptosis of BCR-ABL-expressing
cells in the presence of HS-5 cells. (A) K562 cells were cultured at a concentration of 8 × 104/mL in the presence or absence of HS-5 cells. Cells
were then treated with varying concentrations of imatinib alone or in combination with TG101348 for 72 h. Viable cell numbers were calculated.
Results are representative of three separate experiments. (B) K562 cells were treated with imatinib alone or in combination with TG101348 for
24 h, and total extracts were examined by immunoblotting using anti-phospho ABL, ABL, phospho-Crk-L, Crk-L, phospho-STAT5, STAT5,
phospho-MAPK, Erk-1, cleaved PARP, and β-actin Abs. Blots were scanned and optical densities were determined using ImageJ software. (C) K562
cells were cultured with Z-VAD-fmk (20 μM) and/or TG101348 and imatinib for 24 h. Total extracts were analyzed by immunoblotting using
anti-cleaved caspase-3 and cleaved PARP Abs. Actin was used as the loading control. Data are representative of two separate experiments. Blots
were scanned and optical densities were determined using ImageJ software.
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absence of HS-5 cells (data not shown). However, co-
treatment with TG101348 and imatinib resulted in a
progressive reduction in viable cell number compared
with treatment with imatinib alone (Figure 3A). Fur-
thermore, viable cell numbers of normal samples de-
creased partially after treatment with imatinib and
TG101348 suggests that these treatments were select-
ively, and more effectively influence against leukemia
(Figure 3A). The efficacy of the co-treatment was differ-
ent in each group of primary samples, which may indi-
cate different chemical sensitivities of these compounds.
We next investigated the effect of the inhibitors on
intracellular signaling in CD34-positive primary sam-
ples. We found that BCR-ABL, Crk-L, and STAT5 phos-
phorylation decreased, while PARP activity increased
after the co-treatment (Figure 3B). We investigated the
efficacy of co-treatment with TG101348 and imatinib in
a xenograft model. Growth of tumors decreased consid-
erably in TG101348- and imatinib-treated mice com-
pared with that in control mice. These results indicate
that co-treatment with imatinib and TG101348 is an
effective strategy to reduce expansion of BCR-ABL-
positive cells including CD34-positive primary cells.
Knockdown of JAK2 increased sensitivity to imatinib
We next knocked down JAK2 by transfecting JAK2 small
interfering RNA (siRNA) into K562 cells. Cell lysates
were analyzed by immunoblotting 72 h after transfection
using an anti-JAK2 Ab. We confirmed that Jak2 expres-
sion decreased considerably when compared to that in
control cells (Figure 4A). To test the effect of JAK2
knockdown on K562 cells, we examined the effect of
imatinib on them when cultured in the presence of HS-
5. We observed that the viability of JAK2 siRNA trans-
fected cells was not reduced when compared with that
of control cells (Figure 4B). In contrast, viability of JAK2
siRNA-transfected cells was partially reduced in the
presence of HS-5 cells when compared to control cells
cultured under the same conditions (Figure 4B). Import-
antly, we found that viability of JAK2 siRNA-transfected
K562 cells decreased considerably after imatinib treat-
ment in the presence of HS-5 cells (Figure 4B). Next,
we investigated the effect of imatinib on intracellularsignaling in these cells. We found that BCR-ABL phos-
phorylation in the JAK2 siRNA-transfected K562 cells
was not reduced after imatinib treatment compared to
control cells (Figure 4C). In contrast, we observed that
Crk-L and MAPK phosphorylation decreased after ima-
tinib treatment in JAK2-siRNA transfected K562 cells
(Figure 4C). Thus, these results indicate that JAK2 is in-
volved in the downstream signaling of BCR-ABL.
Detection of cytokines in HS-5 conditioned medium
The HS-5 cell line was treated with TG101348 at different
concentrations for 24 h (Figure 5). We found that STAT5
phosphorylation was partially reduced after TG101348
treatment using immunoblotting analysis (Figure 5A). We
next investigated cytokine levels by assaying HS-5 condi-
tioned medium after 1 day of culture in the presence or
absence of TG101348 using the human cytokine array ac-
cording to the manufacturer’s instructions. We analyzed
36 cytokines simultaneously and evaluated their relative
expression levels. We found that GM-CSF, and IL-6
levels decreased considerably after TG101348 treatment
compared to that in the untreated conditioned medium
(Figure 5B). These results indicate that TG101348 regu-
lates cytokine production in HS-5 cells.
Discussion
Previous studies revealed that BCR-ABL-positive pro-
genitor cells persist in patients with CML despite TKI
therapy. This may be attributable, in part, to quiescent
CML stem cells residing in protected hematopoietic
niches [24]. Hematopoietic growth factors, including cy-
tokines, are secreted by endothelial cells and fibroblasts.
JAK2 phosphorylates STAT5 in normal hematopoietic
stem cells following activation of cytokine receptors.
However, BCR-ABL phosphorylates STAT5 at the same
critical tyrosine residue close to the SH2 domain in
CML cells, and activated STAT5 translocates to the nu-
cleus [14,25].
Residual leukemia cells in bone marrow niches are ex-
posed to many cytokines in situ [26]. Our results indicate
that cytokine-enriched HS-5 conditioned medium pro-
tected CML cells from imatinib. Furthermore, we demon-
strated that the imatinib inhibitory effect decreased when
CML cells were co-cultured with HS-5 cells. This stromal
Figure 3 (See legend on next page.)
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Figure 3 Effects of imatinib and TG101348 on CD34-positive primary cells. (A) CD34-positive CML cells or healthy donor samples were
cultured in the presence of HS-5 cells. Cells were then treated with varying concentrations of imatinib alone or in combination with TG101348 for
72 h. Viable cell numbers were calculated. Results are representative of three separate experiments. (B) CD34-positive primary cells were treated
with the indicated concentrations of imatinib alone or in combination with TG101348 for 24 h. Total cell extracts were analyzed by immunoblotting
using phospho-specific ABL, STAT5, Crk-L, and cleaved PARP Abs. β-actin was used as the loading control. Results are representative of at least three
reproducible experiments. Blots were scanned and optical densities were determined using ImageJ software. (C) In vivo studies were performed as
described in Methods. Tumors were treated with or without imatinib and TG101348 5 days per week, and growth was measured. *p < 0.05, compared
with control mice.
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topoietic progenitor proliferation. Treatment of K562 cells
with imatinib in the presence of HS-5 conditioned
medium resulted in only partial inhibition of cell growth,
indicating that imatinib alone may not be sufficient to
eradicate residual CML cells that reside within a cytokine-
rich microenvironment. Thus, it is important to probe the
cytokine-mediated leukemia stem cell signaling pathways
as targets for combined treatments with TKIs to develop
more efficient therapies for patients with CML.
In this study, we analyzed the ability of cytokine sig-
naling to protect CML cells. A previous study revealed
GM-CSF-mediated imatinib and nilotinib resistance
through BCR-ABL independent activation of the JAK2/
STAT5 pathway [27]. We demonstrated that inhibiting
JAK2 by either JAK2 siRNA transfection or the JAK2 in-
hibitor TG101348 downregulated STAT5 activity. More-
over, STAT5 phosphorylation decreased considerably and
PARP activity increased following co-treatment with ima-
tinib and TG101348 in Ph+ leukemia cells including pri-
mary CD34-positive cells. Inhibiting STAT5 in leukemia
was sufficient to prevent leukemia cell proliferation. JAK2
functions downstream of BCR-ABL. Although we did not
tried to combine the two drugs at their IC50s in this cell
line, we showed that inhibiting JAK2 resulted in reduced
STAT5 activity and enhanced imatinib efficacy even when
leukemia cells were protected by hematopoietic stromal
cells-mediating cytokine/chemokine production.
We also examined the effect of TG101348 on cytokine
expression in HS-5 cells using a cytokine array containing
36 different cytokines. We observed that expression levels
of several cytokines, such as GM-CSF, G-CSF, and IL-6,
decreased considerably after treatment. Because GM-CSF
and IL-6 are involved in maintenance of hematopoietic
stem cells, these cytokines suppress apoptosis and regulate
cell viability, growth, and differentiation [28]. Thus, acti-
vating cytokine-mediated JAK2/STAT5 signaling may cir-
cumvent the need for BCR-ABL signaling and cell survival
[29]. Here, we demonstrated that blocking cytokine signal-
ing using a JAK2 inhibitor in combination with imatinib
might be an effective strategy to eradicate residual CML
cells in vitro and in vivo. Cytokine-mediated signaling may
not be critical for cell survival when BCR-ABL signaling isactivated; however, it is possible that residual CML cells
treated with imatinib can be rescued through a cytokine-
triggered JAK2/STAT5 signaling pathway.
Conclusions
Our results indicate that co-treatment with imatinib and
JAK2 inhibitors may have the potential for targeting re-
sidual CML cells by enhancing imatinib efficiency and
reducing cytokine production by stromal cells. There-
fore, this approach may represent an important thera-
peutic strategy for patients with CML.
Methods
Cell culture and reagents
The BCR-ABL-positive leukemia cell line K562 and human
bone marrow stromal cell line HS-5 were obtained from
the American Type Culture Collection (Rockville, MD,
USA). Cells were cultured in the Roswell Park Memorial
Institute 1640 medium containing 10% fetal bovine serum
and maintained at 37°C in a 5% CO2 humidified atmos-
phere. The JAK2 inhibitor TG101348 was purchased from
Shanghai APIs Chemical (Shanghai, China) and the ABL
kinase inhibitor imatinib was provided by Novartis Pharma
AG (Basel, Switzerland). Stock solutions of TG101348
were prepared in dimethyl sulfoxide, while that of imatinib
was prepared in distilled water. These stock solutions were
further diluted in growth medium to achieve the desired
concentrations. Antibodies (Abs) against phosphor-Abl,
phospho Crk-L, STAT5, MAPK, cleaved caspase-3, and
PARP were purchased from Cell Signaling Technology
(Danvers, MA, USA). Erk-1, Crk-L, and STAT5 Abs were
purchased from BD Biosciences (San Jose, CA, USA). The
anti-Abl Ab was purchased from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA, USA). Other reagents were obtained
from Sigma-Aldrich (St. Louis, MO, USA).
Primary BCR-ABL-positive and normal control cells
This study protocol was approved by the Institutional
Review Board of Tokyo Medical University, and written
informed consent was provided by all patients in accord-
ance with the Declaration of Helsinki. Primary samples
were collected from untreated peripheral blood of pa-
tients with CML or from the bone marrow of normal
Figure 4 JAK2 siRNA transfected K562 cells had increased sensitivity to imatinib. (A) K562 cells were transfected with JAK2 siRNA or a
control siRNA. Cell lysates were analyzed by immunoblotting 72 h after transfection using Jak2 and β-actin Abs. Blots were scanned and optical
densities were determined using the ImageJ system. (B) K562 and siRNA-transfected K562 cells were cultured at a concentration of 8 × 104/mL in
the presence or absence of feeder cells. The cells were treated with 1 μM imatinib for 72 h. Viable cell numbers were calculated. Results are
representative of three separate experiments. (C) K562 and siRNA-transfected K562 cells were treated with imatinib for 24 h, and total extracts
were examined by immunoblotting using anti-phospho ABL, ABL, phospho-Crk-L, Crk-L, phospho-MAPK, Erk-1 and β-actin Abs. Blots were
scanned and optical densities were determined using ImageJ software.
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The peripheral blood was collected in heparinized tubes,
and mononuclear cells were separated using LymphoSe-
pare (Immuno-Biological Laboratories, Minneapolis,
MN, USA). These cells were either used immediately or
cryopreserved in liquid nitrogen until use.Cell proliferation assay
Cells were seeded in 24- or 96-well plates at a density of
8 × 104 or 8 × 103 cells/well. Next, cells were treated with
the inhibitors at the indicated concentrations: imatinib,
100 nM to 2 μM; and TG101348, 100 nM to 1 μM. Vi-
able cells were either counted using trypan blue
Figure 5 Effect of TG101348 on HS-5 cells. (A) HS-5 cells were cultured in the presence of different concentrations of TG101348 for 24 h, and
total extracts were examined by immunoblotting using anti-phospho STAT5, STAT5, and β-actin Abs. Blots were scanned and optical densities
were determined using ImageJ software. (B) HS-5 cells were treated with TG101348 for 24 h and conditioned medium was collected. The relative
levels of 36 different cytokines were analyzed using the Human Cytokine Array Kit. The expression of cytokines was determined using ImageJ
software. Results are representative of three separate experiments. *p < 0.05, TG101348 treatment vs. control.
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(Dojin, Kumamoto, Japan) and measured spectrophoto-
metrically (A450) to determine cell viability. In some exper-
iments, cells were co-cultured with human stromal cells.
After cultivating the HS-5 cells at a density of 1 × 105
cells/well in 24-well plates overnight, the K562 cells were
plated onto the HS-5 cells, cultured for 3 days, and ana-
lyzed for cell proliferation. To analyze the activity of the
soluble factors produced by HS-5 cells, K562 cells were
cultured for 72 h in the presence of HS-5 conditioned
medium from cultures that that were either not treated
with imatinib or treated with the drug at the indicated
concentrations. Cell proliferation was then analyzed.siRNA transfection
siRNAs targeting the JAK family members were pur-
chased from Santa Cruz Biotechnology (sc-39099). K562
cells were transfected with a siRNA targeting JAK2 by
electroporation, as described previously [30].
Immunoblotting
Immunoblotting was performed as described previously
[31]. After different treatments were performed as indi-
cated above, cells were collected by centrifugation and
lysed by sonication using the radioimmunoprecipitation
assay lysis buffer. Protein content in the lysates was de-
termined using a protein assay kit (Bio-Rad Laboratories,
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teins were separated on 4–20% polyacrylamide gels and
transferred to polyvinylidene difluoride membranes. Next,
the membranes were probed using primary Abs of interest
at the appropriate dilutions for 2 h at room temperature.
The blots were visualized by the chemiluminescent method
using the Amersham ECL chemiluminescence kit (GE
Healthcare, Tokyo, Japan). Immunoblots were quantified
using ImageJ software (NIH, Bethesda, MD, USA).
Cytokine array
After culturing HS-5 cells in the presence or absence of
TG101348, the culture medium was collected. Cytokine
levels in the medium were measured using the human
cytokine panel A (Proteome Profiler™) (R&D Systems,
Minneapolis, MN, USA). Horseradish peroxidase sub-
strate was used to detect protein expression, and data
were visualized using Kodak Biomax Light film. Arrays
were scanned and optical densities were determined
using ImageJ software.
In vivo studies
Six-week-old female BALB/c nude mice were purchased
from CLEA Japan Inc. (Tokyo, Japan). Mice were injected
subcutaneously with 1 × 107 Ba/F3 wild-type BCR-ABL
cells. Mice were treated after 5 days with 40 mg/kg ima-
tinib intraperitoneally or 30 mg/kg TG101348 orally or a
combination of the two agents for 5 days per week. Con-
trol mice were treated with phosphate-buffered saline.
Tumor sizes were analyzed every day. The average tumor
weight per mouse (n = 6) was calculated.
Statistical analysis
We used Student’s t-test to determine differences in re-
sponse to the various treatments. p < 0.05 was consid-
ered statistically significant.
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